Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kevin M Budge

Showing results (1-10 of 6) with videos related to

Pageof 1
Sort By:
Antibodies (Basel, Switzerland)|August 22, 2025
Immunogenicity Risk Assessment of Biotherapeutics Using an Ex Vivo B Cell AssayKevin M Budge, Ross Blankenship, Patricia Brown-Augsburger, et al.
Molecular Neurobiology|September 1, 2017
Glycoprotein NMB: an Emerging Role in Neurodegenerative DiseaseKevin M Budge, Matthew L Neal, Jason R Richardson, et al.
Molecular Neurobiology|May 22, 2020
Transgenic Overexpression of GPNMB Protects Against MPTP-Induced NeurodegenerationKevin M Budge, Matthew L Neal, Jason R Richardson, et al.
Antibodies (Basel, Switzerland)|January 23, 2025
Rat as a Predictive Model for Human Clearance and Bioavailability of Monoclonal AntibodiesJason D Robarge, Kevin M Budge, Lucy Her, et al.
Journal of Neuroinflammation|March 10, 2018
The glycoprotein GPNMB attenuates astrocyte inflammatory responses through the CD44 receptorMatthew L Neal, Alexa M Boyle, Kevin M Budge, et al.
FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology|January 10, 2020
Pharmacological inhibition of CSF1R by GW2580 reduces microglial proliferation and is protective against neuroinflammation and dopaminergic neurodegenerationMatthew L Neal, Sheila M Fleming, Kevin M Budge, et al.
Pageof 1

Showing results (1-10 of 6) with videos related to

Sort By:
Pageof 1
Antibodies (Basel, Switzerland)|August 22, 2025
Immunogenicity Risk Assessment of Biotherapeutics Using an Ex Vivo B Cell AssayKevin M Budge, Ross Blankenship, Patricia Brown-Augsburger, et al.
Molecular Neurobiology|September 1, 2017
Glycoprotein NMB: an Emerging Role in Neurodegenerative DiseaseKevin M Budge, Matthew L Neal, Jason R Richardson, et al.
Molecular Neurobiology|May 22, 2020
Transgenic Overexpression of GPNMB Protects Against MPTP-Induced NeurodegenerationKevin M Budge, Matthew L Neal, Jason R Richardson, et al.
Antibodies (Basel, Switzerland)|January 23, 2025
Rat as a Predictive Model for Human Clearance and Bioavailability of Monoclonal AntibodiesJason D Robarge, Kevin M Budge, Lucy Her, et al.
Journal of Neuroinflammation|March 10, 2018
The glycoprotein GPNMB attenuates astrocyte inflammatory responses through the CD44 receptorMatthew L Neal, Alexa M Boyle, Kevin M Budge, et al.
FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology|January 10, 2020
Pharmacological inhibition of CSF1R by GW2580 reduces microglial proliferation and is protective against neuroinflammation and dopaminergic neurodegenerationMatthew L Neal, Sheila M Fleming, Kevin M Budge, et al.
Pageof 1